The phrase “GLP-3” is appearing more often in online peptide discussions, but it can create a basic scientific misunderstanding. There is no established third incretin hormone called GLP-3 that sits after GLP-1 and GLP-2. In current research discussions, “GLP-3” is usually an informal commercial or catalogue label for compounds associated with three receptor pathways.
The clearest way to understand the subject is to separate three different things: biological hormones, receptor targets, and product labels.
GLP-1, GIP and glucagon are three distinct pathways
GLP-1 means glucagon-like peptide-1. GIP means glucose-dependent insulinotropic polypeptide. Glucagon is a separate pancreatic hormone. These names describe distinct signalling systems, not “GLP-1, GLP-2 and GLP-3” versions of one sequence.
Researchers may study compounds designed to activate more than one of these receptors. A dual agonist targets two receptor pathways. A triple agonist targets three.
That is why the phrase “triple-receptor agonist” is more scientifically useful than “GLP-3.” It tells the reader what is being investigated without inventing a new hormone category.
Where retatrutide fits
Retatrutide is an investigational peptide described in peer-reviewed literature as an agonist of the GIP, GLP-1 and glucagon receptors. A randomized phase 2 trial published in The New England Journal of Medicine evaluated it in adults with obesity. The study is important evidence about an investigational drug candidate, but it does not turn “GLP-3” into a recognized hormone name.
The trial record should also be read in context. Phase 2 research is designed to explore efficacy, safety and dose-response questions in a defined participant group. It is not the same as broad regulatory approval or a complete long-term evidence base.
The US National Library of Medicine currently lists ongoing phase 3 research for retatrutide. That continuing programme is another reason to use careful language: the molecule remains under clinical investigation.
Three labels that should not be treated as synonyms
| Term | What it describes |
| GLP-1 | A biological hormone and receptor pathway |
| Triple-receptor agonist | A compound designed to activate three specified receptors |
| GLP-3 | An informal label whose exact meaning depends on the seller or publisher |
The practical rule is simple: when a page uses “GLP-3,” look for the actual molecular identity and the receptor targets. A label alone is not enough to establish composition, identity, purity, approval status or intended use.
Why precise naming matters
Imprecise terminology can blur the line between early research, clinical development and approved medicine. It can also cause readers to assume that two products with the same marketing label contain the same material.
Scientific communication is clearer when it answers five questions:
- What is the molecule?
- Which receptors or pathways are being studied?
- What kind of evidence is available: cell, animal, phase 1, phase 2 or phase 3?
- Which population and endpoints were studied?
- What is the current regulatory status in the relevant country?
These questions are more useful than relying on a shorthand label.
What the evidence does and does not show
The published phase 2 retatrutide trial provides controlled human data for the specific investigational molecule, protocol and participant group studied. It does not validate unrelated products that use similar terminology. It also does not support assuming that every triple-pathway research material is interchangeable.
Regulators make the distinction explicit. The US Food and Drug Administration states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. The agency also says it cannot be used in compounding under US federal law.
That statement concerns the United States, but the underlying reading principle is global: a promising clinical programme and an approved medicine are not the same category.
A better way to write about “GLP-3”
Responsible educational content should:
- define the label before using it;
- name GLP-1, GIP and glucagon as separate pathways;
- identify retatrutide only when the source or catalogue actually means retatrutide;
- distinguish investigational research from approved treatment;
- avoid dosing, administration instructions and personal treatment recommendations;
- link to the primary trial or regulatory source.
This approach is slightly less catchy than repeating a trending label, but it is much more useful to readers.
One catalogue-specific example is the Emirates Peptides GLP-3 research guide, which identifies the three receptor pathways and keeps the material within a research-only context.
The bottom line
“GLP-3” is best treated as an informal catalogue or discussion label, not the name of a third incretin hormone. Triple-receptor research concerns specified receptor pathways, and retatrutide is one investigational molecule in that area. The most reliable explanation always names the molecule, the three targets, the evidence stage and the regulatory status.
Sources
- Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” PubMed: https://pubmed.ncbi.nlm.nih.gov/37366315/
- ClinicalTrials.gov. Retatrutide phase 3b study NCT07357415: https://clinicaltrials.gov/study/NCT07357415
- US Food and Drug Administration. Concerns with unapproved GLP-1 drugs, including retatrutide: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Author bio: Haris writes for the Emirates Peptides editorial team. He focuses on plain-English, source-led explanations of laboratory peptide research and evidence quality.
Disclosure: Emirates Peptides is a UAE supplier of laboratory research materials. This article was prepared with AI assistance; source links are provided for verification. It is educational, is not medical advice, and does not provide instructions for human use.
